PaxMedica, Inc. announced the completion of a type-B meeting with the FDA. During the live meeting, the company discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness caused by Trypanosoma bhodesiense, a rare and fatal parasitic disease if left untreated. PaxMedica has received constructive feedback which will aid in the completion of the remaining work necessary to file a New Drug Application (NDA) expected in the second half of 2024.

Most of the work to achieve this important milestone will focus on completing the production of commercial lots of PAX-101 under CMC regulatory guidelines, underway now and scheduled to conclude in the first half of 2024.